Atractylenolide III Improves Mitochondrial Function and Protects Against Ulcerative Colitis by Activating AMPK/SIRT1/PGC-1α

Figure 4

AT III attenuates DSS-induced mitochondrial dysfunction via AMPK/SIRT1-mediated deacetylation of PGC-1α. (a) The levels of mtDNA were determined using qPCR. (b, c) The activities of complex I and complex IV were measured using commercial kits. (d, e) Representative images of Tom20 expression using immunofluorescent staining and quantification results. Scale bar: 50 μm. (f, g) The expression levels of PGC-1α, NRF-1, NRF-2, and Tfam were examined and quantified by Western blot. (h, i) The expression levels of p-AMPK, AMPK, and SIRT1 were measured and quantified by Western blot. (j, k) The acetylated levels of PGC-1α and quantification results were measured. ^$, compared to control; ^&, compared to DSS.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)